AML Clinical Trial - Epidemiologic Registry PETHEMA LMA 2015

Status Recruiting

Clinical Trial Summary

Epidemiologic and retrospective multicenter registry of all patients diagnosed with de novo or secondary acute myeloid leukemia (AML) in the PETHEMA Group institutions. This study is a non-interventional research regarding diagnosis and therapeutic approach

Clinical Trial Description

To perform this registry, every patient diagnosed with AML in the participant institutions, regardless type of AML and treatment administered, must be reported. It will be required to registry the main characteristics of the patients and AML at diagnosis, as cytomorphologic, immunophenotypic, and cytogenetic results, according to the habitual practice of the centers. The treatment which has been administered by every center of the PETHEMA Group, even when it is considered as supportive care, and evolution of the disease will also be reported (relapse o death). PETHEMA Group will input all the reported information in data bases ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02607059
Study type	Observational [Patient Registry]
Source	PETHEMA Foundation
Contact	Pau Montesinos, Dr
Email	montesinos_pau@gva.es
Status	Recruiting
Phase
Start date	May 2015
Completion date	December 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03118466` - Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia	Phase 2
Not yet recruiting	`NCT06313437` - Revumenib in Combination With 7+3 + Midostaurin in AML	Phase 1
Withdrawn	`NCT03444649` - Epacadostat, Idarubicin and Cytarabine (EIC) in AML	Phase 1
Withdrawn	`NCT02905994` - Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia	Phase 1
Recruiting	`NCT02261779` - Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible	Phase 1/Phase 2
Completed	`NCT00246649` - Stem Cell Transplant With Specially Treated Cells in Treating Patients With Acute Leukemia	N/A
Completed	`NCT00333190` - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation	N/A
Terminated	`NCT04079738` - Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib	Phase 1/Phase 2
Completed	`NCT03466320` - DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2	Phase 1/Phase 2
Withdrawn	`NCT03138395` - iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML	N/A
Terminated	`NCT01570465` - Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
Completed	`NCT04443751` - A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	Phase 1
Terminated	`NCT03761069` - Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias	Phase 1
Completed	`NCT02631993` - Photochemotherapy and Graft-versus-leukemia in Acute-leukemia	N/A
Completed	`NCT02575963` - Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients	Phase 1/Phase 2
Completed	`NCT00780598` - Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML	Phase 2
Completed	`NCT00863148` - Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)	Phase 2
Completed	`NCT00542971` - Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)	Phase 1/Phase 2
Completed	`NCT00761449` - Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5	Phase 2
Completed	`NCT00589082` - DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML	Phase 3